Eventide Asset Management - ALX ONCOLOGY HLDGS INC ownership

ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 76 filers reported holding ALX ONCOLOGY HLDGS INC in Q2 2023. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.

Quarter-by-quarter ownership
Eventide Asset Management ownership history of ALX ONCOLOGY HLDGS INC
ValueSharesWeighting
Q1 2023$3,005,027
-70.4%
664,829
-26.3%
0.06%
-72.5%
Q4 2022$10,165,540
+17.8%
902,0000.0%0.20%
+17.6%
Q3 2022$8,632,000
-64.1%
902,000
+105.0%
0.17%
-47.4%
Q2 2021$24,056,000
+262.5%
439,950
+388.8%
0.32%
+229.6%
Q1 2021$6,637,00090,0000.10%
Other shareholders
ALX ONCOLOGY HLDGS INC shareholders Q2 2023
NameSharesValueWeighting ↓
venBio Partners LLC 9,699,925$46,559,64013.20%
Vivo Capital, LLC 4,220,048$20,256,2302.22%
Logos Global Management LP 1,000,000$4,800,0000.64%
Orbimed Advisors 2,871,000$13,780,8000.29%
Redmile Group, LLC 1,283,289$6,159,7870.29%
BRAIDWELL LP 1,249,900$5,999,5200.19%
Cormorant Asset Management, LP 612,079$2,937,9790.17%
Nan Fung Group Holdings Ltd 41,950$201,3600.16%
Forefront Analytics, LLC 13,769$66,0920.04%
CORNERCAP INVESTMENT COUNSEL INC 35,071$168,3410.03%
View complete list of ALX ONCOLOGY HLDGS INC shareholders